<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>AKT3 drives adenoid cystic carcinoma development in salivary glands.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="AKT3 drives adenoid cystic carcinoma development in salivary glands." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/5806106/4e5b749483cd/CAM4-7-445-g003.jpg"/> </div> <div class="text-side"> <h1>AKT3 drives adenoid cystic carcinoma development in salivary glands.</h1> <p>Dox treatment leads to regression of established tumors. (A). Relative tumor volume upon doxycycline (Dox) treatment of mice measured using a caliper. Treatment was started when tumors reached a volume of 500–750 mm2 (B &amp; C). Representative H&amp;E staining of ACCs in salivary glands of Dt mice w/o treatment and with Dox treatment. (D) Quantitation of tumor area and tumor number using TissueQnostic software. Graphs represent mean ± SD, data were analyzed by Student's t‐test. (n = 3, **P &lt; 0.01).</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29282901/" target="_blank">29282901</a></p><p>Type: Premalignant/Malignant, Category: Adnexal</p>
</div> </div></div></body></html>